DK0862452T3 - Stabiliserende formulering af NGF - Google Patents

Stabiliserende formulering af NGF

Info

Publication number
DK0862452T3
DK0862452T3 DK96937710T DK96937710T DK0862452T3 DK 0862452 T3 DK0862452 T3 DK 0862452T3 DK 96937710 T DK96937710 T DK 96937710T DK 96937710 T DK96937710 T DK 96937710T DK 0862452 T3 DK0862452 T3 DK 0862452T3
Authority
DK
Denmark
Prior art keywords
ngf
stabilizing formulation
stabilizing
formulation
maturation
Prior art date
Application number
DK96937710T
Other languages
Danish (da)
English (en)
Inventor
Young Linda R De
M Lam Xanthe
Tue Nguyen
F Powell Michael
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=24214304&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK0862452(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Genentech Inc filed Critical Genentech Inc
Application granted granted Critical
Publication of DK0862452T3 publication Critical patent/DK0862452T3/da

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18Growth factors; Growth regulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18Growth factors; Growth regulators
    • A61K38/185Nerve growth factor [NGF]; Brain derived neurotrophic factor [BDNF]; Ciliary neurotrophic factor [CNTF]; Glial derived neurotrophic factor [GDNF]; Neurotrophins, e.g. NT-3
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Psychology (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Transition And Organic Metals Composition Catalysts For Addition Polymerization (AREA)
  • Pretreatment Of Seeds And Plants (AREA)
DK96937710T 1995-11-07 1996-10-21 Stabiliserende formulering af NGF DK0862452T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US55468595A 1995-11-07 1995-11-07
PCT/US1996/016881 WO1997017087A1 (en) 1995-11-07 1996-10-21 Stabilizing formulation for ngf

Publications (1)

Publication Number Publication Date
DK0862452T3 true DK0862452T3 (da) 2004-04-05

Family

ID=24214304

Family Applications (1)

Application Number Title Priority Date Filing Date
DK96937710T DK0862452T3 (da) 1995-11-07 1996-10-21 Stabiliserende formulering af NGF

Country Status (18)

Country Link
EP (1) EP0862452B1 (xx)
JP (1) JP4057058B2 (xx)
KR (1) KR100497087B1 (xx)
CN (1) CN1126567C (xx)
AT (1) ATE255903T1 (xx)
AU (1) AU721112B2 (xx)
BR (1) BR9611571B1 (xx)
CA (1) CA2234231C (xx)
DE (1) DE69631063T2 (xx)
DK (1) DK0862452T3 (xx)
ES (1) ES2211991T3 (xx)
HK (1) HK1015261A1 (xx)
IL (1) IL124004A (xx)
MX (1) MX9803342A (xx)
PT (1) PT862452E (xx)
TR (1) TR199800811T2 (xx)
WO (1) WO1997017087A1 (xx)
ZA (1) ZA969290B (xx)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2286137A1 (en) * 1997-04-11 1998-10-22 Roche Diagnostics Gmbh Ngf for the prevention of demyelination in the nervous system
US6113947A (en) * 1997-06-13 2000-09-05 Genentech, Inc. Controlled release microencapsulated NGF formulation
US6171586B1 (en) 1997-06-13 2001-01-09 Genentech, Inc. Antibody formulation
US6663899B2 (en) 1997-06-13 2003-12-16 Genentech, Inc. Controlled release microencapsulated NGF formulation
US6991790B1 (en) 1997-06-13 2006-01-31 Genentech, Inc. Antibody formulation
US7282482B2 (en) 1998-04-08 2007-10-16 The Regents Of The University Of California NGF for the prevention of demyelination in the nervous system
WO2000004913A1 (en) 1998-07-23 2000-02-03 Eli Lilly And Company Fsh and fsh variant formulations, products and methods
US20030166525A1 (en) 1998-07-23 2003-09-04 Hoffmann James Arthur FSH Formulation
CA2452114C (en) * 2001-06-26 2010-11-16 Takeda Chemical Industries, Ltd. Tgf-.beta. superfamily production/secretion promoter
DE10219545A1 (de) * 2002-04-26 2003-11-06 Lang Florian Regulation der Apoptose
KR101105486B1 (ko) 2003-04-02 2012-01-13 아레스 트레이딩 에스.에이. Fsh 및 lh과 비이온성 계면활성제의 액상 약제학적 제제
AR044302A1 (es) * 2003-05-13 2005-09-07 Ares Trading Sa Formulaciones con proteinas liquidas estabilizadas en recipientes farmaceuticos
CN1318087C (zh) * 2003-06-06 2007-05-30 北京三诺佳邑生物技术有限责任公司 去白蛋白神经生长因子制剂
ES2414705T3 (es) 2003-06-20 2013-07-22 Ares Trading S.A. Formulaciones liofilizadas de FSH/LH
DE10333317A1 (de) * 2003-07-22 2005-02-17 Biotecon Therapeutics Gmbh Formulierung für Proteinarzneimittel ohne Zusatz von humanem Serumalbumin (HSA)
CN108348579B (zh) * 2015-04-21 2021-04-27 舒泰神(北京)生物制药股份有限公司 神经生长因子组合物及注射粉剂
WO2017117701A1 (zh) * 2016-01-04 2017-07-13 葡萄王生技股份有限公司 预防听力退化的活性物质、含其的组合物、及其制备方法
CN114252519B (zh) * 2020-09-23 2023-11-24 舒泰神(北京)生物制药股份有限公司 一种测定神经生长因子纯度的方法

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL109350A (en) * 1993-05-12 2001-01-28 Genentech Inc Stable liquid preparations of gamma interferon
US6277828B1 (en) * 1993-08-20 2001-08-21 Syntex (U.S.A.) Inc. Pharmaceutical formulations of nerve growth factor

Also Published As

Publication number Publication date
EP0862452A1 (en) 1998-09-09
HK1015261A1 (en) 1999-10-15
KR100497087B1 (ko) 2005-09-09
CN1201394A (zh) 1998-12-09
PT862452E (pt) 2004-04-30
ATE255903T1 (de) 2003-12-15
JP4057058B2 (ja) 2008-03-05
CA2234231C (en) 2009-04-14
JP2002502358A (ja) 2002-01-22
ES2211991T3 (es) 2004-07-16
BR9611571B1 (pt) 2009-01-13
BR9611571A (pt) 1999-03-30
MX9803342A (es) 1998-09-30
TR199800811T2 (xx) 1998-07-21
AU7518696A (en) 1997-05-29
CN1126567C (zh) 2003-11-05
AU721112B2 (en) 2000-06-22
CA2234231A1 (en) 1997-05-15
IL124004A (en) 2003-10-31
DE69631063D1 (de) 2004-01-22
EP0862452B1 (en) 2003-12-10
DE69631063T2 (de) 2004-09-30
ZA969290B (en) 1998-05-05
WO1997017087A1 (en) 1997-05-15
KR19990067350A (ko) 1999-08-16

Similar Documents

Publication Publication Date Title
DK0862452T3 (da) Stabiliserende formulering af NGF
NO971889D0 (no) Forbindelser og sammensetninger for levering av aktive midler
BR9407278A (pt) Formulações farmacêuticas do fator de crescimento dos nervos
DK0608912T3 (da) Synergistiske mikrobicide sammensætninger
ES2168414T3 (es) Formulaciones de retinoides en microesferas porosas de irritacion reducida y estabilidad aumentada.
ES2082003T3 (es) Deshidrodidemnina b.
FI971536A (fi) Keratinosyytti-kasvutekijän analogeja
TR199800415T1 (en) Farmas�tik form�lasyon.
ES2150233T3 (es) Pirrolo(2,3-c)carbazol-6-onas condensadas que potencian la actividad de interferon gamma.
AU8332791A (en) Oral pharmaceutical compositions containing melatonin
ES2002083A6 (es) Un metodo para preparar derivados de piroglutamida
PT727996E (pt) Formulacoes de febbendazol
AU5355498A (en) 15-fluoro prostaglandins as ocular hypotensives
AU4751797A (en) Defined systems for epithelial cell culture and use thereof
ATE174383T1 (de) Verwendung von tri-n-butylphosphat bei niedrigem ph in lösungen von biologisch aktiven proteinen für eine verbesserte viruzide wirkung
DE69425061D1 (de) Verwendung von einer suspension auf der basis von sucralfatgel als antazidum
ES8705466A1 (es) Un metodo para la preparacion del factor nkbs regulador del cancer humano.